Why the study?
Tuberculosis and ischemic coronary heart disease share risk factors and pathophysiological links forming an unnoticed syndemic, yet their concurrent management poses challenges due to significant pharmacological interactions.
Answers are grounded in this paper and cite their sources.
This review provides a comprehensive overview of the pathophysiological links between tuberculosis and ischemic heart disease and proposes a practical pharmacological algorithm to manage complex drug interactions.
Tuberculosis is an increasing disease that affects about one-third of the global population. In line with the rise of tuberculosis, cardiovascular disease has shown a similar trend, with ischemic coronary heart disease becoming the leading cause of death worldwide. Based on the literature, a relationship can be drawn between tuberculosis and ischemic coronary heart disease through their shared multiple risk factors and a possible pathophysiological substrate linking them. The presentation of these two conditions reported so far is varied: it has been found as the onset of acute coronary syndrome in patients with active tuberculosis, the progressive development of coronary atherosclerosis in patients with latent tuberculosis, among others. Given this possible link and the progressive increase in their incidence rates, we can assert that we are facing an unnoticed syndemic, with their concurrent management posing a challenge due to significant pharmacological interactions. The purpose of this review is to clarify this possible link, propose an approach for diagnosis, and provide a treatment algorithm for the entire spectrum of coronary disease coexisting with tuberculosis according to the current available literature.
No takes yet. Share an insight, caveat, or question.
Moreno et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: